Generated by AI
Assembly Biosciences Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapeutics for serious viral and liver diseases. Its current pipeline includes investigational treatments for recurrent genital herpes, hepatitis B virus, hepatitis D virus, and other infectious conditions, with programs designed to target key stages of viral replication and disease progression. The company also advances research in related areas such as cholestatic liver disease and microbiome-linked disorders through orally delivered therapeutic candidates. Assembly Biosciences Inc. works across discovery, preclinical, and clinical development, positioning itself within the infectious disease and liver disease segments of the biotechnology market. Headquartered in South San Francisco, California, the company concentrates on creating novel treatment approaches intended to address unmet medical needs in virology and liver health.
WebsiteTwo Tower Place
South San Francisco, CA, 94080
United States
The latest articles about ASMB.
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of -111.36% and -63.95%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Summary of Jul 17's posts. Generated by AI.
Summary of Jan 30's posts. Generated by AI.
Summary of Jul 17's posts. Generated by AI.
Investors talking about ASMB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.